These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31070502)

  • 1. Spontaneous multiple cervical artery dissections after alemtuzumab.
    Durand-Dubief F; Marignier R; Berthezene Y; Cottin J; Nighoghossian N; Vukusic S
    Mult Scler; 2020 Mar; 26(3):381-383. PubMed ID: 31070502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Ahrabian D; Neill L; Bell R; Leary SM
    Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis.
    Brannigan J; Jones JL; Stacpoole SRL
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32522766
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical observation during alemtuzumab administration.
    Allen CM; Feng JJ; Willis MD; McGinley M; Ontaneda D; Tallantyre EC; Evangelou N
    Mult Scler Relat Disord; 2020 Jan; 37():101412. PubMed ID: 32172992
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
    Russo CV; Saccà F; Paternoster M; Buonomo AR; Gentile I; Scotto R; Brescia Morra V; Mansueto G
    Mult Scler; 2020 Jan; 26(1):123-126. PubMed ID: 30882274
    [No Abstract]   [Full Text] [Related]  

  • 10. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
    Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
    Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of anaphylaxis to alemtuzumab.
    Nye CJS; Wagner A; Kousin-Ezewu O; Jones JL; Coles AJ
    J Neurol; 2019 Mar; 266(3):780-781. PubMed ID: 30715557
    [No Abstract]   [Full Text] [Related]  

  • 13. Case of alemtuzumab-related alopecia areata management in MS.
    Chan JK; Traboulsee AL; Sayao AL
    Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e516. PubMed ID: 30568994
    [No Abstract]   [Full Text] [Related]  

  • 14. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
    Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
    Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
    Hoffman BM; Zeid NA; Alam U; Caress JB
    Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
    Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
    Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
    Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
    Metz I; Rieckmann P; Kallmann BA; Brück W
    Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
    Rolfes L; Pfeuffer S; Ruck T; Windhagen S; Oschlies I; Pavenstädt HJ; Angenendt L; Wiendl H; Krämer J; Meuth SG
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31704887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.